INDEPENDENT NEWS

PharmaZen forecasts 44% jump in 2018 sales

Published: Wed 16 May 2018 07:14 PM
PharmaZen forecasts 44% jump in 2018 sales as new plant allows toll processing
By Jonathan Underhill
May 16 (BusinessDesk) - PharmaZen, a Christchurch-based manufacturer of plant and animal-based health supplements, is forecasting a 44 percent increase in sales this year and a jump in earnings as the company brings a new plant online.
Turnover at its Waitaki Biosciences operating division is forecast to rise to $10.5 million this year from $7.3 million in 2017, according to a presentation to shareholders at their annual meeting this month. Earnings before interest, tax, depreciation and amortisation is seen rising to $2.5 million from $443,000 while pre-tax profit is $1.5 million from a $352,000 loss in 2017 when major delays installing a new freeze drier disrupted production.
A five-year, $12.5 million capital investment will result in PharmaZen having the largest solvent extraction plant in New Zealand and the biggest freeze drier plant in Australasia with the capacity to dry 3,000 metric tonnes of frozen product a year, it says.
According to the AGM presentation, the company is in the final stages of gaining a licence from Medsafe to produce MCHCal and StimuCal - products aimed at promoting bone health. Its other products include ActiPhen, a freeze-dried kiwifruit powder for digestive health, CassiPure, a blackcurrant extract and PernaTec oil and powder extracted from greenshell mussels.
"What we're experiencing now, in some cases, is quite unprecedented demand," said Steve Caultron, general manager at Waitaki. "We've got some fairly significant opportunities ahead of us in completely new markets where their volume expectations take us to a new level."
In PharmaZen's 2017 annual report, posted on the Unlisted Securities Exchange (USX) where its shares trade, the company said it is "now moving into its next phase including the development of new products. We anticipate an acceleration in investment in intellectual property with significant clinical trial work already scheduled for 2018 and 2019."
The company was likely to review its capitalisation policy "in order that the balance sheet better reflects the significant value in intellectual property that PharmaZen now possesses." It raised $2.4 million in equity capital in the final quarter of 2017 and said it was in talks with strategic partners for additional placements. Total borrowings stood at $8.1 million at year-end, up from $5.5 million a year earlier.
The company now had "an exceptional opportunity" to "increase its presence in the global nutraceutical market," it said in its annual report, which was released on March 26.
PharmaZen shares last traded on Unlisted at 7 cents, giving the company a market value of $13.7 million.
(BusinessDesk)
BusinessDesk
Independent, Trustworthy New Zealand Business News
The Wellington-based BusinessDesk team provides a daily news feed for a serious business audience.
Contact BusinessDesk
Email:

Next in Business, Science, and Tech

Waste work programme to tackle tough problems
By: New Zealand Government
Foreign buyers ban passes third reading
By: New Zealand Government
Fairfax slashes value of NZ business as Nine merger looms
By: BusinessDesk
Commission to sue Viagogo
By: Commerce Commission
Fonterra CEO Spierings goes early after milk price trimmed
By: BusinessDesk
Tyres pollution: Some collectors ignore disposal rules
By: RNZ
Concrete solutions to Auckland’s construction waste
By: New Zealand Government
Greens all talk, no action
By: New Zealand National Party
Councils back the Government’s waste work programme
By: Local Government NZ
Waste levy hike has nothing to do with the environment
By: New Zealand Taxpayers' Union
NZ First Welcomes First Step in Addressing Foreign Ownership
By: New Zealand First Party
REINZ is disappointed foreign buyer ban passes third reading
By: REINZ
KiwiBuild puts the housing market at risk
By: New Zealand National Party
Urban Growth Agenda Warrants Bi-Partisan Support
By: Infrastructure NZ
Consumer NZ welcomes action against Viagogo
By: Consumer NZ
View as: DESKTOP | MOBILEWe're in BETA! Send Feedback © Scoop Media